Nipro Corporation to Acquire Infraredx
Nipro Corporation (Osaka, Japan) has signed a definitive agreement to acquire Infraredx, Inc. (Burlington, Massachusetts).
Nipro Corporation (Osaka, Japan) has signed a definitive agreement to acquire Infraredx, Inc. (Burlington, Massachusetts). Nipro Corporation has broad holdings in pharmaceuticals and medical devices. Infraredx is an intravascular imaging company working to advance the diagnosis and management of coronary artery disease globally.
The agreement combines Nipro’s global cardiovascular portfolio with Infraredx’s industry expertise in near infrared spectroscopy and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States, and continue Infraredx’s mission to provide cardiologists with advanced imaging tools designed to predict heart attacks and prevent them.
“We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease,” Jason Bottiglieri, president and CEO of Infraredx, said in a statement.
The acquisition, which is subject to certain conditions, is expected to close in October 2015.
Best of the Week: EAS Conference Coverage, IR Spectroscopy, Microplastics
November 22nd 2024Top articles published this week include highlights from the Eastern Analytical Symposium, a news article about the infrared (IR) spectroscopy market, and a couple of news articles recapping spectroscopic analysis of microplastics.
FT-IR Analysis of pH and Xylitol Driven Conformational Changes of Ovalbumin–Amide VI Band Study
November 21st 2024This study uses Fourier transform infrared (FT-IR) spectroscopy to analyze how the globular protein ovalbumin's secondary structures transition under varying pH conditions in the presence of the cosolvent xylitol, highlighting the role of noncovalent interactions in these conformational changes.
